Medical Breakthroughs

Beyond Funding: Founder-Led Evidence Unlocks Cardiac AI Revenue

Listen to this article · 6 min listen

Everyone loves to talk about the size of the funding round in healthcare AI, with headlines screaming about multi-million dollar deals. For investors and founders deep in the diagnostic AI weeds, that’s mostly noise. A much better metric is staring us in the face: converting hard clinical evidence into durable commercial accounts. This is about a founder’s real track record, the demonstrable success in turning scientific validation into market share and, critically, net revenue retention, not just the capital they managed to secure. ### Cleerly’s Series C Extension and the Evidence Imperative Cleerly’s $106 million Series C extension in December 2024, led by Insight Partners with Battery Ventures joining, is a perfect example. While a nine-figure raise always gets attention, any experienced investor knows the capital is just the fuel for the engine. The real work is scaling a solution that’s already built on strong clinical validation with a clear line of sight to reimbursement. Cleerly’s program, which focuses on coronary plaque analysis, sits right at this intersection of scientific rigor and commercial reality. This investment highlights a simple truth in healthcare AI: the ability to convert evidence into sales matters far more than the size of the raise. For any diagnostic AI company, especially a Software as a Medical Device (SaMD), the path from a good idea to widespread use is a slog of clinical trials, regulatory approvals, and painstaking payer engagement. This cash infusion is meant to help Cleerly push its mission forward, but its success will be measured by how well that capital solidifies its evidence and expands its paying customer base. ### Decoding the CREDENCE Trial Data A diagnostic AI’s credibility is only as good as its clinical validation. Cleerly has built its founder track record on the back of the CREDENCE trial, which gives us concrete numbers to assess their coronary plaque analysis. The trial showed a per-vessel sensitivity of 75.9 percent and a specificity of 83.4 percent. In plain English, those numbers measure the AI’s skill at finding plaque when it’s there and correctly identifying its absence. To back that up, a pooled analysis of 582 patients and 1,521 vessels produced nearly identical results: 76.2 percent sensitivity and 85.2 percent specificity. This is exactly the kind of granular data VCs need to see. It’s a tangible measurement of diagnostic accuracy, which is the absolute minimum requirement before a hospital will adopt a tool or a payer will consider creating a CPT code for it. This kind of transparency with published outcomes data is the bedrock of our clinical validation score and what separates the best AI healthcare investments from the rest. PubMed article on CREDENCE trial results ### Working through the Payer Field: WPS Government Health Administrators Strong clinical data is necessary, but it’s not sufficient. For a diagnostic AI business to actually scale, it has to get paid, which means winning over the payer world. The American Medical Association approving a CPT® Category I code for Cleerly’s AI-QCT plaque analysis, effective January 1, 2026, was a huge step. That approval, combined with Medicare’s 2024 coverage decision and the fact that major commercial payers like Aetna, UnitedHealthcare, and Cigna (covering over 86 million Americans) followed suit, shows a reimbursement pathway that’s getting wider and deeper. Dealing with entities like WPS Government Health Administrators for Medicare administration and getting that kind of widespread commercial adoption are direct signals of real payer penetration. For a VC, a clear reimbursement strategy is just as important as the clinical data. Why? Because great clinical validation without a plan to get paid creates a “zombie company”, a product that’s clinically sound but starves from a lack of sustainable revenue. A founder’s skill in shepherding those coding and coverage decisions is what determines the long-term health and net revenue retention of the business. This is where the theory of a good investment meets reality. CMS National Coverage Determinations for diagnostic imaging ### The Founder Metric: Evidence Conversion to Net Revenue Retention For a venture-backed diagnostic AI company, a founder’s performance is in the end measured by their success in converting evidence into sticky commercial accounts. The single best metric for this is Net Revenue Retention (NRR). NRR tells you how much your revenue from existing customers is growing, factoring in any downgrades or churn. In the world of diagnostic AI, high NRR is proof that the clinical data you’re showing in sales meetings is actually translating into consistent use and payment. It answers the question directly: are the per-vessel sensitivity and specificity numbers from the CREDENCE trial compelling enough for a health system to integrate the tool and for a payer like WPS Government Health Administrators to keep cutting checks for it? A founder who can point to strong NRR is proving their AI diagnostic is a valuable, integrated piece of the clinical workflow that justifies its cost, not just a neat piece of technology. This is the definitive proof point for anyone investing in healthcare AI, showing both clinical utility and economic sense. SEC EDGAR filings for venture-backed healthcare companies Cleerly’s $106 million Series C extension is a major financial event. But its true meaning will be found in the founder’s ability to turn the powerful CREDENCE trial data into durable, long-term commercial relationships that show up as strong net revenue retention. This is the kind of nuanced, evidence-first thinking that should define any structured investment framework for the healthcare AI sector.

Frequently Asked Questions

What is the primary metric for evaluating a founder’s success in diagnostic AI, beyond funding rounds?

The primary metric is the conversion of rigorous clinical evidence into durable commercial accounts, leading to sustained market penetration and net revenue retention. It is not merely the capital secured, but the demonstrable success in translating scientific validation into revenue.

How important is clinical validation, and what specific data points are crucial for investors?

Clinical validation is paramount, with detailed, granular data on diagnostic accuracy being non-negotiable. For example, the CREDENCE trial’s reported per-vessel sensitivity of 75.9% and specificity of 83.4% provide tangible measures of the AI’s accuracy, which is a prerequisite for clinical adoption and reimbursement.

Beyond clinical efficacy, what other factors are critical for scalable commercial success in diagnostic AI?

Navigating the complex payer landscape and securing appropriate coding and reimbursement are critical. This includes obtaining CPT codes, Medicare coverage, and widespread commercial payer adoption, as a strong clinical validation without a clear reimbursement strategy can hinder sustainable revenue.

What is Net Revenue Retention (NRR) and why is it the definitive metric for diagnostic AI businesses?

NRR reflects the sustained value a company derives from its existing customer base, accounting for expansions, contractions, and churn. In diagnostic AI, high NRR signifies that clinical evidence translates into consistent utilization and payment, proving the AI is a valuable, integrated component of clinical care.

Share
Was this article helpful?

Editorial Team

The Editorial Team at Healthcare AI Investor Guide is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.